(Q37719241)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

The role of sympathetic nervous activity in renal injury and end-stage renal disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Markus P. Schlaich

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Kazuko Masuo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Gavin W Lambert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Murray D Esler

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Toshio Ogihara

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

26 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

published in

Hypertension Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

521-528

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20339374%20AND%20SRC:MED&resulttype=core&format=json

Sympathetic activation in the pathogenesis of hypertension and progression of organ damage

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Sympathetic overactivity in uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Increased cardiac sympathetic drive in renovascular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Chronic kidney disease in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Impact of the obesity epidemic on hypertension and renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Weight gain as a risk factor for clinical diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

The metabolic syndrome and chronic kidney disease in U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Weight gain-induced blood pressure elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Familial hypertension, insulin, sympathetic activity, and blood pressure elevation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Familial obesity, sympathetic activation and blood pressure level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

High plasma norepinephrine levels associated with beta2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Norepinephrine and concentric hypertrophy in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Beta2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

beta2- and beta3-Adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the nordic diltiazem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Renal function, neurohormonal activation, and survival in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Sympathetic activation in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Sympathetic nerve activity in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Renal denervation chronically lowers arterial pressure independent of dietary sodium intake in normal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

The kidney, hypertension, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Levels of renal and extrarenal sympathetic drive in angiotensin II-induced hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Pathogenesis of hypertension in renal failure: role of the sympathetic nervous system and renal afferents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Behaviour of regional adrenergic outflow in mild-to-moderate renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Mechanisms of sympathetic activation in obesity-related hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Human leptin stimulates systemic nitric oxide production in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Sympathetic nerve activity is inappropriately increased in chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Mechanism of renal hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Early renal denervation prevents development of hypertension in growth-restricted offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Strict blood-pressure control and progression of renal failure in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

β2-Adrenoceptor Polymorphisms Relate to Obesity Through Blunted Leptin-Mediated Sympathetic Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Renal protection in hypertensive patients: selection of antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Body mass index and the risk of development of end-stage renal disease in a screened cohort

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Incidence and precursors of hypertension in young adults: the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

End-stage renal disease (ESRD) and its treatment in Japan

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Hormonal mechanisms in blood pressure reduction during hemodialysis in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Influence of sympathetic activity on blood pressure and vascular damage evaluated by means of urinary albumin excretion

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Sustained influence of the renal nerves to attenuate sodium retention in angiotensin hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Leptin induces direct vasodilation through distinct endothelial mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Massive obesity and nephrotic proteinuria with a normal renal biopsy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Alterations in plasma and cerebrospinal fluid norepinephrine and angiotensin II during the development of renal hypertension in conscious dogs

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Increased sympathetic nerve activity in renovascular hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Renal denervation attenuates long-term hypertensive effects of Angiotensin ii in the rat

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021

Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.35

7 January 2021